152 related articles for article (PubMed ID: 31309173)
1. Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity.
Alvarez M; Otano I; Minute L; Ochoa MC; Perez-Ruiz E; Melero I; Berraondo P
Cell Stress; 2019 Jun; 3(7):236-239. PubMed ID: 31309173
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
Perez-Ruiz E; Minute L; Otano I; Alvarez M; Ochoa MC; Belsue V; de Andrea C; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Llacer C; Alvarez M; de Luque V; Molina C; Teijeira A; Berraondo P; Melero I
Nature; 2019 May; 569(7756):428-432. PubMed ID: 31043740
[TBL] [Abstract][Full Text] [Related]
3. Probiotics
Wang T; Zheng N; Luo Q; Jiang L; He B; Yuan X; Shen L
Front Immunol; 2019; 10():1235. PubMed ID: 31214189
[TBL] [Abstract][Full Text] [Related]
4. Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Jacoberger-Foissac C; Blake SJ; Liu J; McDonald E; Triscott H; Nakamura K; Smyth MJ; Teng MW
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199513
[TBL] [Abstract][Full Text] [Related]
5. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.
Hassel JC; Heinzerling L; Aberle J; Bähr O; Eigentler TK; Grimm MO; Grünwald V; Leipe J; Reinmuth N; Tietze JK; Trojan J; Zimmer L; Gutzmer R
Cancer Treat Rev; 2017 Jun; 57():36-49. PubMed ID: 28550712
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF, a magic bullet in cancer immunotherapy?
Montfort A; Dufau C; Colacios C; Andrieu-Abadie N; Levade T; Filleron T; Delord JP; Ayyoub M; Meyer N; Ségui B
J Immunother Cancer; 2019 Nov; 7(1):303. PubMed ID: 31727152
[TBL] [Abstract][Full Text] [Related]
7. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
Hailemichael Y; Johnson DH; Abdel-Wahab N; Foo WC; Bentebibel SE; Daher M; Haymaker C; Wani K; Saberian C; Ogata D; Kim ST; Nurieva R; Lazar AJ; Abu-Sbeih H; Fa'ak F; Mathew A; Wang Y; Falohun A; Trinh V; Zobniw C; Spillson C; Burks JK; Awiwi M; Elsayes K; Soto LS; Melendez BD; Davies MA; Wargo J; Curry J; Yee C; Lizee G; Singh S; Sharma P; Allison JP; Hwu P; Ekmekcioglu S; Diab A
Cancer Cell; 2022 May; 40(5):509-523.e6. PubMed ID: 35537412
[TBL] [Abstract][Full Text] [Related]
10. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
11. Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.
Kong YC; Flynn JC
Front Immunol; 2014; 5():206. PubMed ID: 24904570
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department.
Peyrony O; Tieghem Y; Franchitti J; Ellouze S; Morra I; Madelaine-Chambrin I; Flicoteaux R; Baroudjian B; Azoulay E; Chevret S; Fontaine JP
Emerg Med J; 2019 May; 36(5):306-309. PubMed ID: 30910911
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
Villadolid J; Amin A
Transl Lung Cancer Res; 2015 Oct; 4(5):560-75. PubMed ID: 26629425
[TBL] [Abstract][Full Text] [Related]
14. Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy.
Sun S; Xu L; Zhang X; Pang L; Long Z; Deng C; Zhu J; Zhou S; Wan L; Pang B; Xiao Y
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915876
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.
Giles AJ; Hutchinson MND; Sonnemann HM; Jung J; Fecci PE; Ratnam NM; Zhang W; Song H; Bailey R; Davis D; Reid CM; Park DM; Gilbert MR
J Immunother Cancer; 2018 Jun; 6(1):51. PubMed ID: 29891009
[TBL] [Abstract][Full Text] [Related]
16. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
[No Abstract] [Full Text] [Related]
17. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
19. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune complications of immunotherapy: pathophysiology and management.
Chan KK; Bass AR
BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
